摘要
达格列净作为钠–葡萄糖共转运体2抑制剂的代表药物之一,于2017年在中国上市。该药通过独特的降糖机制而发挥作用,除了降低血糖水平外,还具有降脂、降压等多方面的益处。已有研究证实在射血分数轻度下降和保留型患者中应用达格列净可降低心血管死亡、因心衰住院或心衰紧急就诊风险,这为心血管保护作用提供了有力的支持。本文就达格列净对心血管系统保护机制研究进展做一综述。
Dapagliflozin, one of the representative drugs of sodium-glucose cotransporter 2 inhibitors, was launched in China in 2017. The drug works through a unique glucose-lowering mechanism, and in addition to lowering blood glucose levels, it also has multiple benefits such as lipid-lowering and blood pressure-lowering. Dapagliflozin has been shown to reduce the risk of cardiovascular death, hospitalization for heart failure or emergency heart failure visits in patients with mildly reduced and preserved ejection fraction, which provides strong support for the cardiovascular protective ef-fects. In this article, we present a review of the progress in the study of the protective mechanism of dapagliflozin on the cardiovascular system.
出处
《临床医学进展》
2023年第12期20297-20304,共8页
Advances in Clinical Medicine
